COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme
Clare L. Fasching(Mammoth Biosciences (United States)), Charles Y. Chiu(University of California, San Francisco), Bridget McKay(Mammoth Biosciences (United States)), Alicia Sotomayor-González(University of California, San Francisco), James P. Broughton(Mammoth Biosciences (United States)), Becky Fung(University of California, San Francisco), Vaishnavi Nagesh(Mammoth Biosciences (United States)), Kevin Reyes(University of California, San Francisco), Noah Brazer(University of California, San Francisco), Emma Stanfield(Mammoth Biosciences (United States)), Jessica Streithorst(University of California, San Francisco), Carley G. Hendriks(Mammoth Biosciences (United States)), Jesus Ching(Mammoth Biosciences (United States)), Steve Miller(University of California, San Francisco), Venice Servellita(University of California, San Francisco), Baolin Wang(Anhui Medical University), Rachel N. Deraney(Mammoth Biosciences (United States)), Janice S. Chen(Mammoth Biosciences (United States))
Cited by 44
Related Papers
CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity
|Science|2018|4.4k
CRISPR–Cas12-based detection of SARS-CoV-2
|Nature Biotechnology|2020|2.8k
Programmed DNA destruction by miniature CRISPR-Cas14 enzymes
|Science|2018|1.2k
Enhanced proofreading governs CRISPR–Cas9 targeting accuracy
|Nature|2017|1.2k
Actionable Diagnosis of Neuroleptospirosis by Next-Generation Sequencing
|New England Journal of Medicine|2014|1k